Globus Medical (GMED), a medical device company, is positioned as a strong value stock, despite holding a Zacks #3 (Hold) rank, due to its robust 'A' VGM Score and 'B' Value Style Score, underpinned by an attractive forward P/E of 17.35. Analyst sentiment for fiscal 2025 has improved, with four analysts revising earnings estimates upwards in the last 60 days, pushing the consensus to $3.21 per share, complemented by an average earnings surprise of +10.8%, suggesting potential upside for investors considering its valuation and earnings momentum.
Globus Medical (GMED) presents a nuanced investment case, characterized by a neutral Zacks #3 (Hold) rank but strong underlying quantitative metrics. The medical device company scores an 'A' on the composite VGM Score and a 'B' on its Value Style Score, supported by an attractive forward P/E ratio of 17.35. Positive momentum is evident in its earnings outlook, with four analysts revising fiscal 2025 earnings estimates upward in the last 60 days, lifting the consensus estimate by $0.04 to $3.21 per share. This forward-looking optimism is complemented by a consistent history of beating expectations, reflected in an average earnings surprise of +10.8%. The combination of a favorable valuation, positive estimate revisions, and a track record of earnings beats suggests that the company's fundamental strength may not be fully reflected in its current 'Hold' rating.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment